BeiGene, Ltd. and Duality Biologics aren’t spilling a lot of beans about their licensing deal for a preclinical antibody-drug conjugate (ADC) in solid tumors, but it nevertheless illustrates the growing importance of the drug modality to pharma firms large and small, as well as showing BeiGene’s increasing attention to solid tumors and DualityBio’s interest in pursuing global development of its product candidates.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?